Article
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Leukemia - 1 Feb 2011
Begna K H, Mesa R A, Pardanani A, Hogan W J, Litzow M R, McClure R F, Tefferi A
Abstract excerpt
In a previous study, we reported on the safety and efficacy of low-dose (0.5 mg) pomalidomide and prednisone and pomalidomide alone (2 mg/day), for the treatment of anemia associated with myelofibrosis (MF). The current study examined the value of low-dose pomalidomide alone. The main eligibility criterion was transfusion-dependency or hemoglobin <10 gm per 100 ml. Anemia response was assessed by International...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.